Abstract:For patients affected by severe inherited platelet dysfunctions, e.g. Glanzmann thrombasthenia (GT) or Bernard-Soulier syndrome (BSS), platelet transfusion is frequently needed for controlling spontaneous bleeding, and is always needed when trauma occurs or surgery is performed. For the mild-to-moderate bleeding entities, e.g. storage pool disease, thrombaxane A2 receptor defect, platelet transfusion is usually unnecessary. Transfusion of platelets should be used selectively and sparingly because of the substantial risk of alloimmunization against HLA antigens and/or platelet glycoproteins (GP) αIIb, β(3), or αIIbβ(3) in GT, and GPI-IX-V in BSS, which may lead to refractoriness to therapy. To reduce the risk, HLA-matched single donors of platelets should be used. If such donors are unavailable, leucocyte-depleted blood components should be used. Therapy other than platelet transfusion includes: (i) Prevention (vaccination against hepatitis B, avoidance of non-steroidal anti-inflammatory drugs, preservation of dental hygiene, correction of iron deficiency and prenatal diagnosis). (ii) Topical measures (compression with gauze soaked with tranexamic acid, fibrin sealants, splints for dental extractions and packing for nose bleeds). (iii) Antifibrinolytic agents that are useful for minor surgery and as adjuncts for other treatment modalities. (iv) Desmopressin that increases plasma levels of von Willebrand factor and factor VIII giving rise to increased platelet adhesiveness and aggregation associated with shortened bleeding time. (v) Recombinant factor VIIa (rFVIIa). GT patients have been treated for bleeding episodes by rFVIIa with partial success. The mechanism by which rFVIIa arrests bleeding is probably related to increased thrombin generation by a tissue factor-independent process, enhanced platelet adhesion and restoration of platelet aggregation. (vi) Female hormones. Excessive bleeding during menarche in patients with GT or BSS can be controlled by high doses of oestrogen followed by high doses of oral oestrogen-progestin. Menorrhagia later in life can be managed by continuous oral contraceptives. Depo-medroxyprogesterone acetate administered every 3 months is an alternative when combined oral contraceptives are contraindicated.

Glanzmann's thrombasthenia associated with gastrointestinal angiodysplasias successfully treated with bevacizumab

Methylprednisolone and Plasmapheresis Are Effective for Life-Threatening Diffuse Alveolar Hemorrhage and Gastrointestinal Hemorrhage in Granulomatosis with Polyangiitis

Severe thrombocytopenia associated to bevacizumab in a patient with scleroderma, gastrointestinal angiodysplasias and refractory gastrointestinal bleeding

S3648 Role of Bevacizumab in Hereditary Hemorrhagic Telangiectasia Associated Recurrent Gastrointestinal Bleeding: A Case Report

Catheter Intervention in a Patient with Intracranial Aneurysms and Glanzmann Thrombasthenia Caused by a Novel Homozygous Likely Pathogenic Variant in the ITGA2B Gene

Glanzmann Thrombasthenia 10 Years Later: Progress Made and Future Directions

S3752 From Crisis to Control: Impact of Bevacizumab in Refractory GI Bleed in Hereditary Hemorrhagic Telangiectasia

When Glanzmann Thrombasthenia Encounters Antithrombin Deficiency: How Do We Balance the Risk and Benefit of Antithrombotic Therapy?

Bevacizumab: an option for refractory epistaxis in hereditary haemorrhagic telangiectasia

Novel Homozygous Silent Mutation of ITGB3 Gene Caused Glanzmann Thrombasthenia

Targeting tissue factor pathway inhibitor with concizumab to improve hemostasis in patients with Glanzmann thrombasthenia: an in vitro study

Pregnancy and childbirth in patients with Glanzmann Thrombasthenia

A bispecific antibody approach for the potential prophylactic treatment of inherited bleeding disorders

Treatment of inherited platelet disorders

Efficacy and safety of recombinant activated factor VII in Glanzmann thrombasthenia: A systematic literature review

Cost-effectiveness of bevacizumab therapy in the care of patients with hereditary hemorrhagic telangiectasia

Double jeopardy, glomangiopericytoma and Glanzmann thrombasthenia resulting in recurrent epistaxis: a case report

Alloimmunization in Congenital Deficiencies of Platelet Surface Glycoproteins: Focus on Glanzmann's Thrombasthenia and Bernard–Soulier's Syndrome

How I treat gastrointestinal bleeding in congenital and acquired von Willebrand disease

Management of hereditary hemorrhagic telangiectasia-like symptoms induced by trastuzumab emtansine in a breast cancer patient: case report

One day at a time: Life with Glanzmann thrombasthenia – Qualitative results from the GT 360 study